series-a
Stage
2021
Founded
1
Investors
About
Amber Therapeutics develops the first fully implantable adaptive neuromodulation therapy for mixed urinary incontinence, targeting the pudendal nerve through a minimally invasive procedure to restore normal bladder function in women.
Explore Amber Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.